Advertisement

Mechanism and Prevention Possibilities in Coronary Thrombosis

  • G. V. R. Born
Conference paper

Abstract

If it is accepted that many myocardial infarctions (MI) are caused, in younger as in older patients, by coronary thrombosis (Davies et al. 1979), modern analysis is providing evidence (see Born 1979) that it depends on complex haemodynamic interactions between atherosclerotic lesions and blood constituents, primarily the platelets. These interactions have implications, both positive and negative, for prevention and treatment. Platelet aggregation as the immediate cause of arterial thrombosis is the basis for the world-wide interest in and large-scale trials of platelet-inhibiting agents as potential anti-thrombotic drugs. In principle, one approach to the prevention of arterial thrombosis should be through drugs capable of inhibiting platelet aggregation. Rapidly increasing biochemical and pharmacological knowledge about platelets has revealed potent inhibitors of aggregation with different modes of action. Encouraging results have been obtained recently with models of extra-corporeal circulation, e.g. artificial kidneys in which the thrombotic deposition of platelets can be prevented by adenosine (Richardson et al. 1976) or by prostacyclin (prostaglandin I2) (Bunting et al. personal communcation). It was on the basis of their platelet-inhibiting activities that three established drugs, acetylsalicylic acid (aspirin), dipyridamole (persantin) and sulphinpyrazone (anturane) have been undergoing extensive trials in different well-defined clinical situations arising in consequence of arterial thromboses. Results so far have left considerable uncertainties. All these drugs have actions on many other systems in the body, so that any therapeutic effectiveness need not be due to their actions on platelets.

Keywords

Platelet Aggregation Acetylsalicylic Acid Coronary Thrombosis Arterial Thrombosis Extensive Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. The Anturane Reinfarction Trial Research Group (1978) N Engl J Med 298: 289CrossRefGoogle Scholar
  2. Born, GVR (1979a) Letter. Lancet I: 822Google Scholar
  3. Born GVR ( 1979 b) Plenary lecture to VIII World Congress of Cardiology, Tokyo, September 1978. Excerpta Medica, AmsterdamGoogle Scholar
  4. Born GVR, Wehmeier A (1979) Nature 282: 212PubMedCrossRefGoogle Scholar
  5. Born GVR, Bergqvist D, Arfors KE (1976) Nature 259: 233PubMedCrossRefGoogle Scholar
  6. Davies MJ, Fulton WFM, Robertson WB (1979) J Pathol 127: 99PubMedCrossRefGoogle Scholar
  7. Richardson PD, Galletti PM, Born GVR (1976) Trans Am Soc Artif Intern Organs 22: 22PubMedGoogle Scholar
  8. Seeman P (1972) Pharmacol Rev 24: 583PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • G. V. R. Born
    • 1
  1. 1.Department of PharmacologyKing’s CollegeLondonUK

Personalised recommendations